Fundraising Fox
Carmine Therapeutics
Cambridge, US · Founded 2021 · Delaware corporation · 6 employees on LinkedIn
Find your way into Carmine Therapeutics
273 people in our graph share verified history with the Carmine Therapeutics team — schools, employers, funds. One of them is your warm intro.
Jeff Knoxunlockedknows Minh Le · together at Carmine Therapeutics (overlapped)
×5knows the team · via NUS Yong Loo Lin School of Medicine
×2knows the team · via City University of Hong Kong
×3knows the team · via Institute of Molecular and Cell Biology
knows the team · via Genome Institute of Singapore
Carmine Therapeutics develops gene therapies using non-viral gene transfer vector systems based on extracellular vesicle technology. The company works on delivering genetic medicines and is affiliated with academic research from institutions including MIT and the National University of Singapore.
Founders & leadership
Carmine Therapeutics was founded in 2021 by Minh Le and Tenzin.
ML
Minh LeFounding scientist / Assistant ProfessorMinh Le holds a Ph.D. in Computational and Systems Biology from the Singapore-MIT Alliance and has conducted postdoctoral research on microRNAs at Harvard Medical School. He served as an assistant professor at City University of Hong Kong from 2015 to 2019 and joined the National University of Singapore as an assistant professor in Pharmacology in 2019, where he was promoted to Associate Professor with tenure in 2025; he is co-founder and founding scientist of Carmine Therapeutics.
T
TenzinFounding member; Associate at EVX Ventures
HL
Harvey LodishNamed on SEC filing
LX
Lin XiangqianNamed on SEC filing
DH
Donald HautNamed on SEC filing
EE
Elan EzicksonNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$13.7M disclosed across 1 round · 2022
▶$13.7MraisedNov 2022 · 6 investors · OtherRule 506(b)
▶$13.7MraisedNov 2022 · 6 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Harvey LodishDirector
- Lin XiangqianDirector
- Donald HautExecutive Officer, Director
- Elan EzicksonDirector
- Offering amount
- $13.7M
- Amount sold
- $13.7M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
LifeMine Therapeutics16 shared keywordsLifeMine is a biopharmaceutical company that uses data science and advanced methods to accelerate drug discovery and develop precision medicines across therapeutic areas.
Bioworld9 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Carmine Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Carmine Therapeutics do?
- Carmine Therapeutics develops gene therapies using non-viral gene transfer vector systems based on extracellular vesicle technology. The company works on delivering genetic medicines and is affiliated with academic research from institutions including MIT and the National University of Singapore.
- Who founded Carmine Therapeutics?
- Carmine Therapeutics was founded by Minh Le, Tenzin in 2021.
- How much funding has Carmine Therapeutics raised?
- Carmine Therapeutics has disclosed $13.7M raised across 1 round.
- Where is Carmine Therapeutics headquartered?
- Carmine Therapeutics is headquartered in Cambridge, US.